BACKGROUND: The viral load of asymptomatic SAR-COV-2 positive (ASAP) persons has been equal to that of symptomatic patients. On the other hand, there are no reports of ST-elevation myocardial infarction (STEMI) outcomes in ASAP patients. Therefore, we evaluated thrombus burden and thrombus viral load and their impact on microvascular bed perfusion in the infarct area (myocardial blush grade, MBG) in ASAP compared to SARS-COV-2 negative (SANE) STEMI patients. METHODS: This was an observational study of 46 ASAP, and 130 SANE patients admitted with confirmed STEMI treated with primary percutaneous coronary intervention and thrombus aspiration. The primary endpoints were thrombus dimension + thrombus viral load effects on MBG after PPCI. The secondary endpoints during hospitalization were major adverse cardiovascular events (MACEs). MACEs are defined as a composite of cardiovascular death, nonfatal acute AMI, and heart failure during hospitalization. RESULTS: In the study population, ASAP vs. SANE showed a significant greater use of GP IIb/IIIa inhibitors and of heparin (p < 0.05), and a higher thrombus grade 5 and thrombus dimensions (p < 0.05). Interestingly, ASAP vs. SANE patients had lower MBG and left ventricular function (p < 0.001), and 39 (84.9%) of ASAP patients had thrombus specimens positive for SARS-COV-2. After PPCI, a MBG 2-3 was present in only 26.1% of ASAP vs. 97.7% of SANE STEMI patients (p < 0.001). Notably, death and nonfatal AMI were higher in ASAP vs. SANE patients (p < 0.05). Finally, in ASAP STEMI patients the thrombus viral load was a significant determinant of thrombus dimension independently of risk factors (p < 0.005). Thus, multiple logistic regression analyses evidenced that thrombus SARS-CoV-2 infection and dimension were significant predictors of poorer MBG in STEMI patients. Intriguingly, in ASAP patients the female vs. male had higher thrombus viral load (15.53 ± 4.5 vs. 30.25 ± 5.51 CT; p < 0.001), and thrombus dimension (4.62 ± 0.44 vs 4.00 ± 1.28 mm2; p < 0.001). ASAP vs. SANE patients had a significantly lower in-hospital survival for MACE following PPCI (p < 0.001). CONCLUSIONS: In ASAP patients presenting with STEMI, there is strong evidence towards higher thrombus viral load, dimension, and poorer MBG. These data support the need to reconsider ASAP status as a risk factor that may worsen STEMI outcomes.
BACKGROUND: The viral load of asymptomatic SAR-COV-2 positive (ASAP) persons has been equal to that of symptomatic patients. On the other hand, there are no reports of ST-elevation myocardial infarction (STEMI) outcomes in ASAP patients. Therefore, we evaluated thrombus burden and thrombus viral load and their impact on microvascular bed perfusion in the infarct area (myocardial blush grade, MBG) in ASAP compared to SARS-COV-2 negative (SANE) STEMI patients. METHODS: This was an observational study of 46 ASAP, and 130 SANE patients admitted with confirmed STEMI treated with primary percutaneous coronary intervention and thrombus aspiration. The primary endpoints were thrombus dimension + thrombus viral load effects on MBG after PPCI. The secondary endpoints during hospitalization were major adverse cardiovascular events (MACEs). MACEs are defined as a composite of cardiovascular death, nonfatal acute AMI, and heart failure during hospitalization. RESULTS: In the study population, ASAP vs. SANE showed a significant greater use of GP IIb/IIIa inhibitors and of heparin (p < 0.05), and a higher thrombus grade 5 and thrombus dimensions (p < 0.05). Interestingly, ASAP vs. SANE patients had lower MBG and left ventricular function (p < 0.001), and 39 (84.9%) of ASAP patients had thrombus specimens positive for SARS-COV-2. After PPCI, a MBG 2-3 was present in only 26.1% of ASAP vs. 97.7% of SANE STEMI patients (p < 0.001). Notably, death and nonfatal AMI were higher in ASAP vs. SANE patients (p < 0.05). Finally, in ASAP STEMI patients the thrombus viral load was a significant determinant of thrombus dimension independently of risk factors (p < 0.005). Thus, multiple logistic regression analyses evidenced that thrombus SARS-CoV-2 infection and dimension were significant predictors of poorer MBG in STEMI patients. Intriguingly, in ASAP patients the female vs. male had higher thrombus viral load (15.53 ± 4.5 vs. 30.25 ± 5.51 CT; p < 0.001), and thrombus dimension (4.62 ± 0.44 vs 4.00 ± 1.28 mm2; p < 0.001). ASAP vs. SANE patients had a significantly lower in-hospital survival for MACE following PPCI (p < 0.001). CONCLUSIONS: In ASAP patients presenting with STEMI, there is strong evidence towards higher thrombus viral load, dimension, and poorer MBG. These data support the need to reconsider ASAP status as a risk factor that may worsen STEMI outcomes.
Authors: Anne Kimball; Kelly M Hatfield; Melissa Arons; Allison James; Joanne Taylor; Kevin Spicer; Ana C Bardossy; Lisa P Oakley; Sukarma Tanwar; Zeshan Chisty; Jeneita M Bell; Mark Methner; Josh Harney; Jesica R Jacobs; Christina M Carlson; Heather P McLaughlin; Nimalie Stone; Shauna Clark; Claire Brostrom-Smith; Libby C Page; Meagan Kay; James Lewis; Denny Russell; Brian Hiatt; Jessica Gant; Jeffrey S Duchin; Thomas A Clark; Margaret A Honein; Sujan C Reddy; John A Jernigan Journal: MMWR Morb Mortal Wkly Rep Date: 2020-04-03 Impact factor: 17.586
Authors: Daniel Modin; Brian Claggett; Caroline Sindet-Pedersen; Mats Christian Højbjerg Lassen; Kristoffer Grundtvig Skaarup; Jens Ulrik Stæhr Jensen; Michael Fralick; Morten Schou; Morten Lamberts; Thomas Gerds; Emil Loldrup Fosbøl; Matthew Phelps; Kristian Hay Kragholm; Mikkel Porsborg Andersen; Lars Køber; Christian Torp-Pedersen; Scott D Solomon; Gunnar Gislason; Tor Biering-Sørensen Journal: Circulation Date: 2020-10-15 Impact factor: 29.690
Authors: Fizzah A Choudry; Stephen M Hamshere; Krishnaraj S Rathod; Mohammed M Akhtar; R Andrew Archbold; Oliver P Guttmann; Simon Woldman; Ajay K Jain; Charles J Knight; Andreas Baumbach; Anthony Mathur; Daniel A Jones Journal: J Am Coll Cardiol Date: 2020-07-14 Impact factor: 24.094
Authors: Lan Shen; Lin Qiu; Li Wang; Hengye Huang; Dong Liu; Ying Xiao; Yi Liu; Jingjin Jin; Xiulan Liu; Dao Wen Wang; Ben He; Ning Zhou Journal: Sci Rep Date: 2021-12-13 Impact factor: 4.379
Authors: Manuela De Michele; Giulia d'Amati; Martina Leopizzi; Marta Iacobucci; Irene Berto; Svetlana Lorenzano; Laura Mazzuti; Ombretta Turriziani; Oscar G Schiavo; Danilo Toni Journal: J Hematol Oncol Date: 2022-08-16 Impact factor: 23.168
Authors: Celestino Sardu; Raffaele Marfella; Francesco Prattichizzo; Rosalba La Grotta; Giuseppe Paolisso; Antonio Ceriello Journal: J Clin Med Date: 2022-03-12 Impact factor: 4.241